November 20, 2026
Andamertinib Benzoate Capsules (安比锐®) Companion Diagnostic Kit Receives NMPA Approval

On November 20, 2026, Guangzhou Burning Rock Dx Co., Ltd. (NASDAQ: BNR, Burning Rock) and Beijing Avistone Biotechnology Co., Ltd. (Avistone) jointly announced that the companion diagnostic kit for Andamertinib Benzoate Capsules (安比锐®, Andamertinib), developed through their collaboration, has received approval from China’s National Medical Products Administration (NMPA). The kit is approved for detecting EGFR exon 20 insertion (exon20ins) mutations in patients with non-small cell lung cancer (NSCLC), supporting the identification of eligible patients and informed treatment decisions.


Andamertinib, an EGFR exon 20 insertion (exon20ins) inhibitor independently developed by Avistone Pharmaceutical (Ningbo) Co., Ltd. (Ningbo Avistone), a wholly owned subsidiary of Avistone, received conditional approval from the NMPA on April 30, 2026. It is indicated for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an exon 20 insertion mutation in EGFR.


On November 14, 2026, Andamertinib was included for the first time in China’s 2026 National Reimbursement Drug List (NRDL), which will take effect on January 1, 2027, potentially improving access to and affordability of this innovative treatment.

Learn More
August 09, 2023
Burning Rock announced a China collaboration with AstraZeneca
Learn More
January 03, 2023
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
Learn More
June 01, 2022
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
Learn More
June 01, 2022
Burning Rock Announces the Launch of China's First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study
Learn More
June 01, 2022
Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits
Learn More
March 15, 2022
Burning Rock Secures Second NGS Kit Approval from the NMPA
Learn More
November 17, 2021
Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass™ Target
Learn More
August 03, 2021
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development
Learn More
April 29, 2021
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
Learn More
1 2 3 4
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."